Yuhan Corp
KRX:000100

Watchlist Manager
Yuhan Corp Logo
Yuhan Corp
KRX:000100
Watchlist
Price: 116 800 KRW -1.1% Market Closed
Market Cap: 8.6T KRW
Have any thoughts about
Yuhan Corp?
Write Note

Yuhan Corp
Other Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Yuhan Corp
Other Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Yuhan Corp
KRX:000100
Other Current Liabilities
â‚©236.1B
CAGR 3-Years
17%
CAGR 5-Years
10%
CAGR 10-Years
14%
SK Biopharmaceuticals Co Ltd
KRX:326030
Other Current Liabilities
â‚©110.9B
CAGR 3-Years
76%
CAGR 5-Years
74%
CAGR 10-Years
N/A
Hanmi Science Co Ltd
KRX:008930
Other Current Liabilities
â‚©110.4B
CAGR 3-Years
37%
CAGR 5-Years
28%
CAGR 10-Years
15%
Hanmi Pharm Co Ltd
KRX:128940
Other Current Liabilities
â‚©128.3B
CAGR 3-Years
-5%
CAGR 5-Years
7%
CAGR 10-Years
9%
S
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
Other Current Liabilities
â‚©18.7B
CAGR 3-Years
6%
CAGR 5-Years
7%
CAGR 10-Years
10%
C
Celltrion Pharm Inc
KOSDAQ:068760
Other Current Liabilities
â‚©28.3B
CAGR 3-Years
-8%
CAGR 5-Years
11%
CAGR 10-Years
16%
No Stocks Found

Yuhan Corp
Glance View

Market Cap
8.6T KRW
Industry
Pharmaceuticals

In the bustling landscape of South Korea's pharmaceutical industry, Yuhan Corp. stands out as a venerable institution with a rich legacy and a forward-thinking approach. Founded in 1926, Yuhan has carved out a respected space in the market through its commitment to developing, manufacturing, and distributing a wide array of pharmaceutical and healthcare products. The company operates across multiple segments, focusing on prescription drugs, over-the-counter medications, and consumer health products that cater to various needs from chronic diseases to everyday health care. Yuhan’s product portfolio includes a combination of in-house innovations and collaborations with global leaders, which has allowed it to build a sustainable revenue stream and secure a substantial market share both domestically and internationally. At the core of Yuhan's business model is the strategic integration of research and development with commercial prowess. The company invests significantly in R&D to stay ahead of industry trends and meet evolving patient needs. This focus on innovation is complemented by strategic partnerships and licensing agreements with international pharmaceutical corporations, allowing Yuhan to introduce groundbreaking therapies to the Korean market. Additionally, Yuhan capitalizes on its robust distribution network, ensuring wide accessibility and penetration of its products. These efforts not only reinforce Yuhan’s position as a leader in the pharmaceutical sector but also fuel its steady financial growth, providing a reliable return on investment through a combination of direct sales and strategic partnerships.

Intrinsic Value
55 502.27 KRW
Overvaluation 52%
Intrinsic Value
Price

See Also

What is Yuhan Corp's Other Current Liabilities?
Other Current Liabilities
236.1B KRW

Based on the financial report for Sep 30, 2024, Yuhan Corp's Other Current Liabilities amounts to 236.1B KRW.

What is Yuhan Corp's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 10Y
14%

Over the last year, the Other Current Liabilities growth was 26%. The average annual Other Current Liabilities growth rates for Yuhan Corp have been 17% over the past three years , 10% over the past five years , and 14% over the past ten years .

Back to Top